Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review

Serum sickness is an immune-complex-mediated systemic illness that can occur after treatment with monoclonal or polyclonal antibodies such as Rituxan (Rituximab) or antithymocyte globulin (Thymoglobulin), respectively. Since Rituximab is now being used as an adjuvant treatment for acute humoral reje...

Full description

Saved in:
Bibliographic Details
Main Authors: Amarpreet Sandhu, Antonia Harford, Pooja Singh, Eduardo Alas
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2012/234515
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549995167875072
author Amarpreet Sandhu
Antonia Harford
Pooja Singh
Eduardo Alas
author_facet Amarpreet Sandhu
Antonia Harford
Pooja Singh
Eduardo Alas
author_sort Amarpreet Sandhu
collection DOAJ
description Serum sickness is an immune-complex-mediated systemic illness that can occur after treatment with monoclonal or polyclonal antibodies such as Rituxan (Rituximab) or antithymocyte globulin (Thymoglobulin), respectively. Since Rituximab is now being used as an adjuvant treatment for acute humoral rejection and its prevalence to cause serum sickness is comparable to Thymoglobulin-associated serum sickness (20% versus 27%), it should be considered a potential cause of serum sickness after rejection treatment. In kidney transplant patients, there are no case reports where patient received both Thymoglobulin and Rituximab before developing serum sickness. We are reporting a patient who developed serum sickness after receiving Thymoglobulin and Rituximab that led us to consider Rituximab as one of the potential causes in this patient’s serum sickness. Since diagnosis of serum sickness is clinical, and Rituximab use has expanded into treatment of glomerulonephritis and acute humoral rejection, it should be considered as a potential offender of serum sickness in these patient populations. There are not any evidence-based guidelines or published clinical trials to help guide therapy for antibody-induced serum sickness; however, we successfully treated our case with three doses of Methylprednisone 500 mg intravenously. Further studies are needed to evaluate Rituximab-associated serum sickness in nephrology population to find effective treatment options.
format Article
id doaj-art-4ce05f362a8e446995b223d43d996a13
institution Kabale University
issn 1687-9627
1687-9635
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-4ce05f362a8e446995b223d43d996a132025-02-03T06:07:54ZengWileyCase Reports in Medicine1687-96271687-96352012-01-01201210.1155/2012/234515234515Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature ReviewAmarpreet Sandhu0Antonia Harford1Pooja Singh2Eduardo Alas3Department of Nephrology, The University of New Mexico, Albuquerque, NM 87131, USADepartment of Nephrology, The University of New Mexico, Albuquerque, NM 87131, USADepartment of Nephrology, The University of New Mexico, Albuquerque, NM 87131, USADepartment of Nephrology, The University of New Mexico, Albuquerque, NM 87131, USASerum sickness is an immune-complex-mediated systemic illness that can occur after treatment with monoclonal or polyclonal antibodies such as Rituxan (Rituximab) or antithymocyte globulin (Thymoglobulin), respectively. Since Rituximab is now being used as an adjuvant treatment for acute humoral rejection and its prevalence to cause serum sickness is comparable to Thymoglobulin-associated serum sickness (20% versus 27%), it should be considered a potential cause of serum sickness after rejection treatment. In kidney transplant patients, there are no case reports where patient received both Thymoglobulin and Rituximab before developing serum sickness. We are reporting a patient who developed serum sickness after receiving Thymoglobulin and Rituximab that led us to consider Rituximab as one of the potential causes in this patient’s serum sickness. Since diagnosis of serum sickness is clinical, and Rituximab use has expanded into treatment of glomerulonephritis and acute humoral rejection, it should be considered as a potential offender of serum sickness in these patient populations. There are not any evidence-based guidelines or published clinical trials to help guide therapy for antibody-induced serum sickness; however, we successfully treated our case with three doses of Methylprednisone 500 mg intravenously. Further studies are needed to evaluate Rituximab-associated serum sickness in nephrology population to find effective treatment options.http://dx.doi.org/10.1155/2012/234515
spellingShingle Amarpreet Sandhu
Antonia Harford
Pooja Singh
Eduardo Alas
Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
Case Reports in Medicine
title Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
title_full Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
title_fullStr Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
title_full_unstemmed Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
title_short Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
title_sort is thymoglobulin or rituximab the cause of this serum sickness a case report of serum sickness dilemma and literature review
url http://dx.doi.org/10.1155/2012/234515
work_keys_str_mv AT amarpreetsandhu isthymoglobulinorrituximabthecauseofthisserumsicknessacasereportofserumsicknessdilemmaandliteraturereview
AT antoniaharford isthymoglobulinorrituximabthecauseofthisserumsicknessacasereportofserumsicknessdilemmaandliteraturereview
AT poojasingh isthymoglobulinorrituximabthecauseofthisserumsicknessacasereportofserumsicknessdilemmaandliteraturereview
AT eduardoalas isthymoglobulinorrituximabthecauseofthisserumsicknessacasereportofserumsicknessdilemmaandliteraturereview